TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7945744

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.01 mg/kg SC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-212 (20 mg PO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3111514

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally four times daily for 4 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally twice daily for 4 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Glibenclamide administered alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glibenclamide with cimetidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glibenclamide with ranitidine
Number of subjects: 15
Study: 31425385

Group type: EXPERIMENTAL
Intervention: ECCONLY contraction at 110% 1RM
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ECCONLY contraction at 130% 1RM
Number of subjects: 32

Group type: COMPARATOR
Intervention: CONONLY contraction at 90% 1RM
Number of subjects: 32

Group type: COMPARATOR
Intervention: ECCONLY contraction at 90% 1RM
Number of subjects: 32
Study: 29933369

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Moderate intensity sustained exercise (EX)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Observational waitlist control
Number of subjects: 413
Study: 27523814

Group type: EXPERIMENTAL
Intervention: External application of ligustrazine combined with holistic nursing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Compound clotrimazole cream (Control)
Number of subjects: 32
Study: 23869585

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 23027184

Group type: EXPERIMENTAL
Intervention: Repetitive step training with preparatory visual cues
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lower limb strength training
Number of subjects: 28
Study: 20537645

Group type: EXPERIMENTAL
Intervention: Intradialytic leg ergometry exercise for 30 min during each hemodialysis session for 8 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intradialytic leg ergometry exercise
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sedentary subjects in the experimental group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sedentary subjects in the control group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Active subjects in the experimental group
Number of subjects: 71
Study: 19080629

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study: 15705011

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75 to 225 mg/day)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 12869713

Group type: EXPERIMENTAL
Intervention: Development of restricted leukoaraiosis (LA)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Development of widespread leukoaraiosis (LA)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Occurrence of strokes in patients who developed LA
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Small deep infarcts in patients who developed LA
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Progression from restricted to widespread LA
Number of subjects: 596
Study: 10680105

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 0.05 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rocuronium 0.06 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: cisatracurium 0.01 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 8983613

Group type: EXPERIMENTAL
Intervention: mannitol 0.3 g/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 28
Study: 2015475

Group type: EXPERIMENTAL
Intervention: Light reflection rheography
Number of subjects: 124
Study: 7199328

Group type: EXPERIMENTAL
Intervention: Midazolam (Ro 21-3981, Dormicum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 30445999

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention program
Number of subjects: 240

Group type: COMPARATOR
Intervention: Letrozole (oral fertility medication)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Myo-inositol (supplement)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 27902622

Group type: EXPERIMENTAL
Intervention: Penetration acupuncture treatment on head combined with conventional treatment (treatment group [TG])
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional treatment only (control group [CG])
Number of subjects: 82
Study: 23295099

Group type: EXPERIMENTAL
Intervention: Immediate loading with a fixed temporary bridge
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (unloaded for 3 months)
Number of subjects: 50
Study: 22974108

Group type: EXPERIMENTAL
Intervention: 30-minute brief interactive session combining structured advice and motivational interviewing techniques delivered by the school learning mentor (level 1 condition, n=2 schools)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 60-minute session involving family members delivered by the school learning mentor (level 2 condition, n=3 schools)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Provision of an advice leaflet (control condition, n=2 schools)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 and 12 months for all participants
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ten-question Alcohol-Use Disorders Identification Test as a secondary outcome measure
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EQ-5D-Y and a modified short service use questionnaire for health and social resource costs
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 28-day timeline follow back questionnaire at 12-month follow-up
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Qualitative evaluation with young people, school staff, learning mentors, and parents
Number of subjects: 7
Study: 20353458

Group type: EXPERIMENTAL
Intervention: 300 IU recombinant FSH
Number of subjects: 131

Group type: COMPARATOR
Intervention: 225 IU recombinant FSH
Number of subjects: 131
Study: 18852875

Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16154855

Group type: EXPERIMENTAL
Intervention: Daily 3-hour fast infusions of arsenic trioxide (As2O3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily slow, continuous infusions of arsenic trioxide (As2O3)
Number of subjects: 0
Study: 15320641

Group type: EXPERIMENTAL
Intervention: Lift Day (LD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 10655437

Group type: EXPERIMENTAL
Intervention: New guidelines for tumor response evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined assessment of target and nontarget lesions
Number of subjects: 0
Study: 9170398

Group type: EXPERIMENTAL
Intervention: Short-acting nifedipine 30 mg/d
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Short-acting diltiazem 90 mg/d
Number of subjects: 1115

Group type: COMPARATOR
Intervention: No calcium antagonist
Number of subjects: 1115
Study: 1487549

Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g
Number of subjects: 11
Study: 2984710

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette containing 100, 200, or 250 micrograms/kg THC
Number of subjects: 0
Study: 31356878

Group type: EXPERIMENTAL
Intervention: ASP7962 (100 mg BID)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: naproxen (500 mg BID)
Number of subjects: 215

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 215
Study: 30146144

Group type: EXPERIMENTAL
Intervention: Structured Cognitive-Behavioral Therapy (CBT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Less-Structured Cognitive-Behavioral Therapy (CBT)
Number of subjects: 69
Study: 26429567

Group type: EXPERIMENTAL
Intervention: Mechanical debridement (MD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency chondroplasty (RF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: KOOS assessment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Joint space width
Number of subjects: 60
Study: 24743428

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study: 22775128

Group type: EXPERIMENTAL
Intervention: Intergroup anxiety
Number of subjects: 0
Study: 20472865

Group type: EXPERIMENTAL
Intervention: Agar nasal catheter
Number of subjects: 26

Group type: COMPARATOR
Intervention: Continuously perfusing nasal catheter
Number of subjects: 26
Study: 19045975

Group type: EXPERIMENTAL
Intervention: Standard care plus contingency management
Number of subjects: 1687

Group type: EXPERIMENTAL
Intervention: Standard care plus motivational enhancement
Number of subjects: 1687

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1687
Study: 15886380

Group type: EXPERIMENTAL
Intervention: 250 mg/d of DG-031
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 500 mg/d of DG-031
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 750 mg/d of DG-031
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: DG-031 (higher doses)
Number of subjects: 191
Study: 12652180

Group type: EXPERIMENTAL
Intervention: RV + MCV -> Can
Number of subjects: 10

Group type: COMPARATOR
Intervention: RV -> SVC + Can
Number of subjects: 10
Study: 9792571

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (5, 10, and 20 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (1, 2, and 4 mg/d)
Number of subjects: 12
Study: 8704419

Group type: EXPERIMENTAL
Intervention: Nourishing the Liver treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invigorating the Spleen control
Number of subjects: 0
Study: 2533509

Group type: EXPERIMENTAL
Intervention: 4-session, 10-week intervention focused on enhancing perceived control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-contact group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 904879

Group type: EXPERIMENTAL
Intervention: Iridocapsular lenses
Number of subjects: 200

Group type: COMPARATOR
Intervention: Iris-clip lenses
Number of subjects: 200
Study: 29168127

Group type: EXPERIMENTAL
Intervention: 0.70 mg/kg DAA-I
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.08 mg/kg DAA-I
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg DAA-I
Number of subjects: 3
Study: 26610858

Group type: EXPERIMENTAL
Intervention: ADT plus Docetaxel (D)
Number of subjects: 385

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 385
Study: 24045586

Group type: EXPERIMENTAL
Intervention: Meclizine 12.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meclizine 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meclizine (both doses)
Number of subjects: 24
Study: 22972857

Group type: EXPERIMENTAL
Intervention: Composites (bisphenol‐A‐diglycidyl‐dimethacrylate composite for permanent teeth, urethane‐dimethacrylate compomer for primary teeth)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Composites (for girls)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Amalgam (for girls)
Number of subjects: 474
Study: 18332760

Group type: EXPERIMENTAL
Intervention: Round bar attachment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ball attachment
Number of subjects: 26
Study: 16515109

Group type: EXPERIMENTAL
Intervention: Human amniotic membrane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Temporalis fascia
Number of subjects: 50
Study: 12439775

Group type: EXPERIMENTAL
Intervention: Increased training over 4 days
Number of subjects: 12
Study: 10416915

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (3 mg/kg for men, 3.75 mg/kg for women)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study: 7501338

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 2360920

Group type: EXPERIMENTAL
Intervention: One‐year exercise program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sedentary control condition
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Baseline data and one‐year change data
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 79
Study: 113838

Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI), 5 mg/kg, administered intramuscularly daily during the second separation.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (no DMI treatment) during the second separation.
Number of subjects: 7
Study: 6408235

Group type: EXPERIMENTAL
Intervention: Cereal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucose polymers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 16
Study: 30917842

Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine plus nab-paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant S-1 plus nab-paclitaxel with SBRT
Number of subjects: 0
Study: 29402332

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 480 mg (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 330
Study: 24165306

Group type: EXPERIMENTAL
Intervention: Cutting diathermy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 31

Group type: COMPARATOR
Intervention: Photographed wounds assessed by surgeons
Number of subjects: 31
Study: 24203065

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 23062189

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg/day increasing to 300 or 450 mg/day)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 498
Study: 20680680

Group type: COMPARATOR
Intervention: Epirubicin plus paclitaxel (ET)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Epirubicin, paclitaxel and capecitabine (TEX)
Number of subjects: 287
Study: 17953762

Group type: EXPERIMENTAL
Intervention: Clindamycin cream treatment
Number of subjects: 9025
Study: 16087950

Group type: EXPERIMENTAL
Intervention: CAF-Z (CAF followed by 5 years of monthly goserelin)
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: CAF-ZT (CAF followed by 5 years of monthly goserelin and daily tamoxifen)
Number of subjects: 1503

Group type: COMPARATOR
Intervention: CAF (six cycles of cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 1503
Study: 12198267

Group type: EXPERIMENTAL
Intervention: Cigarette advertisement (Benson & Hedges)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cigarette advertisement (Marlboro)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Photograph of a packet of cigarettes (Control)
Number of subjects: 100
Study: 9617725

Group type: EXPERIMENTAL
Intervention: Cryo/Cuff with continuous circulating ice water (Group 1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cryo/Cuff with room temperature water (Group 2)
Number of subjects: 78
Study: 7663592

Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral temperature measurement
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ear-based temperature measurement
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Axillary temperature measurement
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral or ear-based temperatures
Number of subjects: 13
Study: 2630344

Group type: EXPERIMENTAL
Intervention: Endocapsular cataract extraction
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard extracapsular procedure
Number of subjects: 176
Study: 909754

Group type: EXPERIMENTAL
Intervention: High doses of metenolone during MOPP chemotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: MOPP chemotherapy without androgenotherapy (implied control)
Number of subjects: 32
Study: 31793398

Group type: EXPERIMENTAL
Intervention: Tiotropium-Olodaterol combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium alone
Number of subjects: 0
Study: 31161202

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (intervention relaxation group)
Number of subjects: 64
Study: 27646197

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: L-DOPA and Placebo
Number of subjects: 85
Study: 25964034

Group type: EXPERIMENTAL
Intervention: Normal scrubber
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Partly-failed scrubber
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Absent scrubber
Number of subjects: 30
Study: 22716932

Group type: EXPERIMENTAL
Intervention: Fluid Deprivation (FD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fully hydrated control condition
Number of subjects: 20
Study: 21284549

Group type: EXPERIMENTAL
Intervention: Minimally invasive non-surgical technique (MINST)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Minimally invasive surgical technique (MIST)
Number of subjects: 29

Group type: COMPARATOR
Intervention: MIST
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patient perception of discomfort/pain and satisfaction
Number of subjects: 29
Study: 19407262

Group type: EXPERIMENTAL
Intervention: Direct switch from subcutaneous rHuEPO to intravenous darbepoetin (group 1)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Indirect switch from subcutaneous rHuEPO to intravenous darbepoetin after 2 months of subcutaneous darbepoetin (group 2)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intravenous rHuEPO switched to intravenous darbepoetin (control group)
Number of subjects: 154
Study: 17385588

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Entonox plus placebo
Number of subjects: 9
Study: 15459145

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sequential antibiotic treatment
Number of subjects: 129
Study: 11003192

Group type: EXPERIMENTAL
Intervention: Face guard helmets provided to intervention teams
Number of subjects: 238

Group type: COMPARATOR
Intervention: No face guard helmets (comparison teams)
Number of subjects: 238
Study: 8994895

Group type: EXPERIMENTAL
Intervention: E‐BEHAVE‐AD rating scale
Number of subjects: 49
Study: 1449389

Group type: EXPERIMENTAL
Intervention: Gastroduodenoanastomosis for gastric drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Duodenum plasty (drainage of the duodenum)
Number of subjects: 60
Study: 2869574

Group type: EXPERIMENTAL
Intervention: terbutaline (beta‐2 agonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: prenalterol (beta‐1 agonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OP‐CCK (sincalide), 80 ng X kg‐1 X h‐1
Number of subjects: 12
Study: 30527839

Group type: EXPERIMENTAL
Intervention: Vilaprisan 0.5 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vilaprisan 1.0 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vilaprisan 2.0 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vilaprisan 4.0 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vilaprisan (≥1.0 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vilaprisan
Number of subjects: 300
Study: 29952886

Group type: EXPERIMENTAL
Intervention: Negative-pressure fixation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Film dressing
Number of subjects: 13
Study: 26848792

Group type: EXPERIMENTAL
Intervention: 4-week dose reduction group
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: 26-week dose reduction group
Number of subjects: 374

Group type: COMPARATOR
Intervention: No-dose-reduction group
Number of subjects: 374
Study: 26215396

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (5 g · kg(‐1) · d(‐1))
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal protein (NP) diet (2 g · kg(‐1) · d(‐1))
Number of subjects: 28
Study: 23800880

Group type: EXPERIMENTAL
Intervention: Moderate exercise (300 kcal/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High exercise (600 kcal/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sedentary living (Control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both exercise groups (Moderate and High)
Number of subjects: 61
Study: 20939639

Group type: EXPERIMENTAL
Intervention: Implementation intention-only condition
Number of subjects: 4391

Group type: EXPERIMENTAL
Intervention: Implementation intention conditions
Number of subjects: 4391

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 4391

Group type: EXPERIMENTAL
Intervention: Measuring anticipated regret
Number of subjects: 4391

Group type: EXPERIMENTAL
Intervention: Questionnaire completion
Number of subjects: 4391

Group type: COMPARATOR
Intervention: No-questionnaire control condition
Number of subjects: 4391